Skip to content
akaturk Academic measurement
Sign in Sign up

OpenAlex topic

Phosphodiesterase function and regulation

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 774 works 13 author topics

Works

774 works

  1. Selexipag for the Treatment of Pulmonary Arterial Hypertension 2015
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    BACKGROUND: In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension. METHODS: In this event-driven, phase 3, randomized, double-blind, placebo-controlled trial, we randomly assigned 1156 patients with pulmonary ar…

  2. Cognitive endophenotypes of bipolar disorder: A meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives 2009
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 97.8%

    No abstract yet.

  3. Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives 2007
    YÖKSİS SJR Q1 JCR Q2 OpenAlex top 10% OpenAlex 94.0%

    No abstract yet.

  4. Synthesis and studies on antidepressant and anticonvulsant activities of some 3 2 furyl pyrazoline derivatives 2007
    YÖKSİS SJR Q1 JCR Q2 OpenAlex top 10% OpenAlex 94.0%

    No abstract yet.

  5. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1) results from the multicentre, Phase 2, randomised, double blind, placebo-controlled study 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.5%

    No abstract yet.

  6. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.6%

    No abstract yet.

  7. The International Society for Bipolar Disorders Battery for Assessment of Neurocognition ISBD BANC 2010
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.0%

    OBJECTIVES: Although cognitive impairment is recognized as an important clinical feature of bipolar disorder, there is no standard cognitive battery that has been developed for use in bipolar disorder research. The aims of this paper were to identify the cognitive measures from the literature that show the greatest ma…

  8. Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study 2007
    SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.1%

    No abstract yet.

  9. Nerandomilast in Patients with Progressive Pulmonary Fibrosis 2025
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. Nerandomilast has been shown to slow the progression of idiopathic pulmonary fibrosis, but an assessment of its effects in other types of progressive pulmon…

  10. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene 1997
    OpenAlex top 10% OpenAlex 96.3%

    We have isolated and characterized complete cDNAs for two isoforms (HSPDE4D4 and HSPDE4A5) encoded by the human PDE4D gene, one of four genes that encode cAMP-specific rolipram-inhibited 3',5'-cyclic nucleotide phosphodiesterases (type IVPDEs; PDE4 family). The HSPDE4D4 and HSPDE4D5 cDNAs encode proteins of 810 and 74…

  11. Meta-analysis of longitudinal studies of cognition in bipolar disorder: comparison with healthy controls and schizophrenia 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 96.3%

    BACKGROUND: Bipolar disorder (BP) is associated with significant cognitive impairment. Recent evidence suggests that cognitive deficits are already evident after first-episode mania. However, it is not clear whether BP is associated with further decline in cognitive functions in individuals with established illness. A…

  12. Nerandomilast in Patients with Progressive Pulmonary Fibrosis 2025
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory properties. Nerandomilast has been shown to slow the progression of idiopathic pulmonary fibrosis, but an assessment of its effects in other types of progressive pulmon…

Academicians

13 academicians